Sudarshan Pharma's record carries three consecutive clean audit opinions, but the clean opinions sit alongside a dense web of unresolved disputes, related-party activity, and a persistent gap between reported profit and operating cash. The most material items are ₹59.13 crore of disputed tax demands with nothing paid under protest, a rejected insurance claim booked as exceptional, and a board that has repeatedly approved promoter pay raises and warrant issues with minimal public shareholder participation.
Key findings
- Sudarshan Pharma carries ₹59.13 crore of disputed tax demands and a rejected insurance claim
Major- Disputed statutory dues not deposited as at 31 March 2026 comprise GST, interest and penalty of ₹1,773.40 lakhs pending at Commissioners (Appeal) for periods 2017-2018 to 2024-2025, with nothing paid under protest. Disputed income tax of ₹4,139.20 lakhs is pending at Commissioner (Appeals) across three assessment years, also with nothing paid under protest. The insurance claim of ₹2.82 crore for damage at Arihant Warehouse, Bhiwandi was rejected on technical grounds and recognised under exceptional items in FY2025-26. - Operating cash flow has persistently failed to back reported profit
Major- Cumulative CFO of ₹10 crore equals 0.18x of cumulative PAT less other income of ₹54 crore over the seven years through FY2026. FY2026 standalone CFO was negative ₹2.30 crore against PAT of ₹23.37 crore, a CFO/PAT ratio of -0.10x. The company "resorts mainly on long-term debt obligations to fund operations" as at March 31, 2026, with standalone cash and cash equivalents of only ₹10.90 lakhs. - Sudarshan Pharma has built a dense web of related-party approvals and transactions
Major- The FY2025-26 Board's Report states "No material related party transactions as per SEBI Listing Regulations; no transactions to be reported in Form AOC-2," while the same year's Corporate Governance report states "there were materially significant transactions with related parties during FY". Shareholders approved a ₹500 crore loan/guarantee/securities authorisation at the 16th AGM on 30 September 2024. The board approved issue of up to 9,00,000 warrants to promoters at ₹169.83 per warrant, aggregating up to ₹15,28,47,000, with 25% upfront payment received. - Sudarshan Pharma has secured authority to borrow and create charges up to Rs.2,500 crore
Major- Shareholders passed special resolutions on 14th June 2025 authorising the board to borrow and to create charges up to Rs.2,500 crore, each with 13,92,63,810 shares (100% of votes cast) in favour. The FY2025-26 standalone working capital facility of Rs.24.5 crore is repayable on demand and secured by hypothecation of entire current assets, exclusive charges on promoter/director properties, and personal guarantees of promoters and directors. The company disclosed FCCB issuance of up to USD 20 million, amounting to Rs.191.86 crore, with no defaults in coupon payment as of 18th May 2026. - Promoter family controls the board and has repeatedly used approvals to raise pay and allot warrants
Major- Mr. Hemal Mehta and Mr. Sachin Mehta each had their basic salary increased from Rs.6,00,000 to Rs.8,00,000 per month effective 1 April 2025. At the 1 October 2024 EGM, the resolution to issue 9,00,000 warrants to promoters passed with only 7 members voting 3,14,600 shares, all 100% in favour. At the 7 February 2025 postal ballot, the resolution to issue 4,30,00,000 warrants passed with only 4 members voting 9,94,000 shares, all 100% in favour. - Sudarshan Pharma expanded from one dormant subsidiary to eight entities in three years
Major- The group grew from 1 wholly-owned subsidiary as of 31 March 2023 to 8 subsidiaries as of 31 March 2026. Four of the eight subsidiaries' financial statements were unaudited and furnished by management for FY2025-26, reporting aggregate total assets of ₹16.91 crore and total revenues of ₹8.04 crore. Four subsidiaries had yet to commence operations as of 31 March 2026, including Sudarshan Pharma Lifescience Private Limited, incorporated 19 March 2021, five years earlier. - First-time Ind AS adoption reshaped the balance sheet through fair-value elections
Minor- Sudarshan Pharma voluntarily adopted Ind AS for the first time with transition date April 1, 2024. Standalone net deferred tax asset increased from ₹4.64 crore as at March 31, 2025 to ₹19.39 crore as at March 31, 2026. Investment properties were carried at fair value of ₹24.37 crore as at March 31, 2026, based on independent valuer assessment. - Clean audit opinions for three years, with a recurring internal controls exception
Minor- NGST & Associates issued unqualified opinions on standalone and consolidated financial statements for FY2025-26, FY2023-24, and FY2022-23, with no key audit matters reported. The Directors' Responsibility Statement for FY2024-25 states internal financial controls are adequate and operating effectively "except that the credit given to the overseas buyers in the previous year(s)". CARO clause xix for FY2025-26 states no material uncertainty that the company cannot meet liabilities falling due within one year from the balance sheet date.
What to watch
- Promoter warrant payment. The remaining 75% (₹11,46,35,250) on promoter warrants is due on or before 17 June 2026.
- FCCB obligations. Coupon payments and any conversion or redemption of the USD 20 million FCCB issuance, as disclosed in announcements dated 18th May 2026 and 21st May 2026.
- Ishwari divestment. Completion of the divestment of subsidiary Ishwari Healthcare Private Limited is expected by 31 Dec 2026, which may resolve the pending CARO report issuance for that subsidiary.
- Borrowing authority utilisation. The Rs.2,500 crore borrowing and charge-creation authority approved by shareholders on 14th June 2025.
Bottom line: This is an audited record with clean opinions, but the clean opinions sit on top of a balance sheet carrying ₹59.13 crore of disputed tax demands, a CFO that has covered only a fraction of reported profit over seven years, and a governance pattern where promoter approvals pass with a handful of votes. The risk is concentrated in the gap between what the filings state and what the approvals authorise. Watch the warrant payment, the FCCB obligations, and whether the disputed demands get resolved.